San Antonio Military Medical Center Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2001
NCT00841399
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (4)

e39 peptide vaccine (2 trials)

e39 vaccine (1 trial)

j65 vaccine (1 trial)

nelipepimut-s (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Endometrial Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4